EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial

Addition von Carboplatin zu sequenzieller Taxan-Anthracyclin-Neoadjuvanstherapie beim triple-negativen Mammakarzinom: Phase-III-randomisierte kontrollierte Studie

Sudeep Gupta iD, Nita Nair iD, Rohini W Hawaldar iD, Shalaka Joshi iD, Seema Gulia, Tanuja Shet, Rajiv Sarin iD, Vani Parmar iD, Sangeeta Desai iD, Jaya Ghosh iD, Tabassum Wadasadawala iD, Vaibhav Vanmali und 10 weitere

Journal of Clinical Oncology · 2026-01 · 44 (1) · 9-19

DOI: 10.1200/jco-25-01023 ↗

Auf einen Blick

In dieser Phase-III-Studie war Carboplatin mit einem besseren Gesamtüberleben verbunden, der Unterschied im ereignisfreien Überleben war nicht signifikant. Der Nutzen zeigte sich nur bei prämenopausalen Patientinnen.

Fragestellung

Verbessert die Zugabe von Carboplatin zur standardisierten Taxan-Anthracyclin-Neoadjuvanz bei TNBC das ereignisfreie und das Gesamtüberleben?

Methode

Phase-III-randomisierte kontrollierte Studie mit Stratifizierung nach Stadium und Menopausenstatus; Vergleich Carboplatin plus Paclitaxel, dann Anthracyclin plus Cyclophosphamid, versus gleiche Chemotherapie ohne Carboplatin.

Ergebnisse

Von 720 randomisiert eingeschlossenen Patient:innen gingen 717 in die modifizierte Intention-to-treat-Analyse ein. EFS: HR 0,80 (95 %-KI 0,62–1,03; P=.081). OS: HR 0,74 (95 %-KI 0,57–0,97; P=.029).

Schlussfolgerung der Autor:innen

Carboplatin erhöhte das EFS nicht signifikant, verbesserte aber das OS bei TNBC; der Nutzen war auf prämenopausale Patientinnen beschränkt.

Kernaussagen

  • EFS: HR 0,80 (95 %-KI 0,62–1,03); nicht signifikant
  • OS: HR 0,74 (95 %-KI 0,57–0,97); signifikant
  • Mehr Myelosuppression Grad ≥3 unter Carboplatin

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2026-01. Verfasst von Sudeep Gupta und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tata Memorial Centre, Mumbai, India. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Carboplatin, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE We evaluated the survival impact of adding platinum to standard taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer (TNBC). METHODS In this phase III trial, patients with TNBC were randomly assigned, after stratification by stage and menopausal status, to receive neoadjuvant chemotherapy comprising once-per-week carboplatin (AUC-2) plus paclitaxel (100 mg/m 2 ) for 8 weeks, followed by four cycles of anthracycline plus cyclophosphamide, or same chemotherapy without carboplatin. The primary end point was event-free survival (EFS), and secondary end points were overall survival (OS) and pathologic complete response. This is the prespecified primary analysis of this study. RESULTS Of 720 patients randomly assigned between April 2010 and January 2020, 717 (platinum 361, control 356) were included in modified intention-to-treat analysis. At median follow-up of 67.6 months, in platinum and control arms, there were 111/361 and 131/356 EFS events (hazard ratio [HR], 0.80 [95% CI, 0.62 to 1.03]; two-sided unstratified P = .081), with 5-year EFS of 70.7% (95% CI, 65.8% to 75.6%) and 64.1% (95% CI, 59.0% to 69.2%), respectively, and 94/361 and 121/356 deaths (HR, 0.74 [95% CI, 0.57 to 0.97]; nominal P = .029), with 5-year OS of 74.4% and 66.8%, respectively. In premenopausal patients, EFS (HR, 0.61 [95% CI, 0.43 to 0.84]; nominal P = .003; 5-year EFS 75.0% v 59.6%) and OS (HR, 0.57 [95% CI, 0.40 to 0.82]; nominal P = .002; 5-year OS 78.2% v 64.6%) were significantly higher, while in postmenopausal patients, EFS (HR, 1.19 [95% CI, 0.80 to 1.78]; nominal P = .386) and OS (HR, 1.06 [95% CI, 0.70 to 1.61]; nominal P = .772) were not significantly different, in platinum versus control arm. There was statistically significant interaction between study intervention and menopausal status for EFS and OS, with a benefit of adding platinum in premenopausal but not in postmenopausal patients. There was more grade ≥3 myelosuppression in carboplatin arm, but there was no difference in nonhematologic toxicities. CONCLUSION Carboplatin did not significantly increase EFS but significantly increased the OS in patients with TNBC, with benefits confined to premenopausal patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCarboplatinAntineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyHumansFemaleMiddle AgedAnthracyclinesAdultAgedTaxoidsPaclitaxelBridged-Ring Compounds

Substanzen

CarboplatinAnthracyclinesTaxoidsPaclitaxeltaxaneBridged-Ring Compounds

Autor:innen und Institutionen

  • Department of Medical Oncology, Tata Memorial Centre, Mumbai, India.
  • Department of Medical Oncology, Homi Bhabha National Institute, Mumbai, India.
  • Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India.
  • Department of Surgical Oncology, Homi Bhabha National Institute, Mumbai, India.
  • Tata Memorial Centre, Mumbai, India.
  • Homi Bhabha National Institute, Mumbai, India.

ORCID-Profile: Sudeep Gupta, Nita Nair, Rohini W Hawaldar, Shalaka Joshi, Rajiv Sarin, Vani Parmar, Sangeeta Desai, Jaya Ghosh, Tabassum Wadasadawala, Pallavi Parab, Asawari Patil, Garvit Chitkara, Sushmita Rath, Jyoti Bajpai, Rima Pathak, Palak Popat, Rajendra A Badwe

Zitieren

APA

Gupta, S., Nair, N., Hawaldar, R. W., Joshi, S., Gulia, S., Shet, T., Sarin, R., Parmar, V., Desai, S., Ghosh, J., Wadasadawala, T., Vanmali, V., Panhale, T., Parab, P., Patil, A., Chitkara, G., Rath, S., Bajpai, J., Pathak, R., …, & Badwe, R. A. (2026). Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial. Journal of Clinical Oncology, 44(1), 9-19. https://doi.org/10.1200/jco-25-01023

Vancouver

Gupta S, Nair N, Hawaldar RW, Joshi S, Gulia S, Shet T, et al. Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial. Journal of Clinical Oncology. 2026;44(1):9-19. doi:10.1200/jco-25-01023

BibTeX
@article{Gupta2026,
  author = {Gupta, Sudeep and Nair, Nita and Hawaldar, Rohini W and Joshi, Shalaka and Gulia, Seema and Shet, Tanuja and Sarin, Rajiv and Parmar, Vani and Desai, Sangeeta and Ghosh, Jaya and Wadasadawala, Tabassum and Vanmali, Vaibhav and Panhale, Tejal and Parab, Pallavi and Patil, Asawari and Chitkara, Garvit and Rath, Sushmita and Bajpai, Jyoti and Pathak, Rima and Popat, Palak and Thakur, Meenakshi and Badwe, Rajendra A},
  title = {Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {1},
  pages = {9--19},
  doi = {10.1200/jco-25-01023}
}
Kostenlos starten →